News
OKYO
1.520
+0.66%
0.010
Weekly Report: what happened at OKYO last week (0803-0807)?
Weekly Report · 5d ago
Weekly Report: what happened at OKYO last week (0727-0731)?
Weekly Report · 08/03 09:16
OKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial
TipRanks · 07/28 11:28
Okyo Pharma CSO Raj Patil purchases 3,363 shares at $1.49
TipRanks · 07/28 11:25
OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share
Benzinga · 07/28 11:08
OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026
TipRanks · 07/27 11:27
Weekly Report: what happened at OKYO last week (0720-0724)?
Weekly Report · 07/27 09:17
OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial
TipRanks · 07/23 16:27
Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38
TipRanks · 07/23 16:05
OKYO Pharma CEO Boosts Stake With Nasdaq Share Purchase
TipRanks · 07/23 11:27
OKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per Share
Benzinga · 07/23 11:01
OKYO Pharma Announces Purchase of Shares by Director
Barchart · 07/23 11:00
OKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial
TipRanks · 07/22 16:28
Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share
TipRanks · 07/22 16:05
OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial
TipRanks · 07/22 14:27
Okyo Pharma says CDO Gary Jacob purchases 3,500 shares for $1.40 per share
TipRanks · 07/22 14:05
OKYO Pharma Says Gary Jacob, Chief Development Officer And Director, Increases His Holdings With Purchase Of 3,500 Ordinary Shares On NASDAQ At $1.40 Per Share
Benzinga · 07/22 14:02
Okyo Pharma CMO Flavio Mantelli purchases 20,000 shares at $1.40
TipRanks · 07/22 11:31
OKYO Pharma CMO Boosts Stake Ahead of Planned Global Phase 3 Trial
TipRanks · 07/22 11:27
OKYO Pharma Says Chief Medical Officer, Flavio Mantelli, Purchases 20,000 Of Its Ordinary Shares On NASDAQ At $1.40 Per Share
Benzinga · 07/22 11:08
More
Webull provides a variety of real-time OKYO stock news. You can receive the latest news about OKYO PHARMA LTD through multiple platforms. This information may help you make smarter investment decisions.
About OKYO
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.